WSAAI 2020 58th Annual Scientific Session

February 2, 2020 to February 6, 2020

This year's meeting will cover novel diagnostics and therapeutics involved in severe asthma, the prevention of food allergies as well as cutting edge treatments for food allergies, address the skin as the largest immune organ and discuss other immunodeficiency and hypersensitivity disease.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 22 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commerical Support
This activity is supported by medical education grants from CSL Behring, DBV Technologies, Grifols, GlaxoSmithKline, Optinose, Kaleo, Shire, Sanofi


 

Target Audience

Allergists and Allied Healthcare Providers

Learning Objectives

Upon completion of this activity, participants should be able to:
- Recognize the different monoclonal antibody therapies for severe asthma and future agents in the drug pipeline
- Learn how gastroenterologists approach patients with mast cell disorders
- Recognize the current and potential roles of biologics to treat chronic rhinosinusitis
- Follow a world-expert in primary immunodeficiencies on how she approaches the diagnosis and treatment of PIDD
- Recognize the benefit or working with gastroenterologists in co-managing inflammatory conditions like eosinophilic esophagitis (EoE)
- Discover novel triggers for hypersensitivity skin diseases such as contact dermatitis
- Recognize how allergists can actively treat food allergies
 

Additional information
Disclosure: 

Disclosure Policy                                                                                           ______                       

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months.  All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations.  It is required that disclosure be provided to the learners prior to the start of the activity.  Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist.  Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.  Disclosure in no way implies that the information presented is biased or of lesser quality.  It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.  Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
 

All identified conflicts of interest have been resolved.
 

The individuals listed below disclose the following financial relationships:

Anna Feldweg, MD​ – Speaker
Employee – UpToDate
Author – UpToDate

Luz Fonacier, MD, FACAAI, FAAAAI – Speaker
Consultant – AbbVie, Regeneron
Contractor – Pfizer, Regeneron, Shire

Matthew J. Hamilton, MD – Speaker
Advisory Board Member – Allakos, Pfizer, Takeca
Consultant – Oshi
Research – GlaxoSmithKline

Anju T. Peters, MD, MSCI – Speaker
Advisory Board Member – AstraZeneca, Optinose, Sanofi Regeneron
Research Support – AstraZeneca, Optinose

Carina Venter, PhD, RD – Speaker
Consultant – DBV Technologies, Nestlé
Speaker – Abbott, MJN, Nutricia

Brian P. Vickery, MD – Speaker
Advisory Board Member – Allergenis, LLC
Scientific Advisory Board Member – Aimmune Therapeutics
Speaker – Thermo-Fisher
Sponsored Research – Aimmune Therapeutics, DBV Technologies, Genentech, Regeneron Pharmaceuticals

Prescott G. Woodruff, MD, MPH – Speaker
Consultant – Amgen, Genentech, GlaxoSmithKline, Glenmark Pharmaceuticals, NGM Pharma, Regeneron, Theravance

Matthew Bowdish, MD – Planner, Moderator, Reviewer
Speaker – AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Advisory Board Member – AstraZeneca, GlaxoSmithKline, Shire
Independent Contractor – Genentech

Jennifer Namazy, MD – Planner, Moderator
Consultant – GlaxoSmithKline
Advisory Board Member – Genentech

Steve Machtinger, MD – Planner, Moderator
Advisory Board Member – ALK, Genentech

Warner Carr, MD – Planner, Moderator
Consultant – Aimmune , AstraZeneca, Glenmark , Regeneron, Sanofi, Teva
Speaker – AstraZeneca, Glenmark , Optinose , Regeneron, Sanofi, Teva

Andrew White, MD – Planner
Speaker – AstraZeneca, Regeneron/Sanofi
Advisory Board Member – Optinose, ALK-Abello

Neal Jain, MD – Planner
Speaker – AstraZeneca, Novartis, Regeneron, Sanofi/Genzyme
Advisory Board Member – AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi/Genzyme
Consultant – Circassia, Regeneron, Sanofi/Genzyme

The following have no relevant financial relationships to disclose:

Charlotte Cunningham-Rundles, MD, PhD – Speaker
Daniel L. Kastner, MD, PhD – Speaker
Jonathan Parsons, MD, MSc, FCCP – Speaker
Karol Anderson – Planner
Rene Anderson-Cowell, MD – Planner
David Elkayam, MD – Planner

 

 

Course summary
Available credit: 
  • 22.00 AMA PRA Category 1 Credit™
  • 22.00 Attendance
Course opens: 
02/02/2020
Course expires: 
02/06/2022
Event starts: 
02/02/2020 - 3:00pm
Event ends: 
02/06/2020 - 5:45pm
Rating: 
5

Available Credit

  • 22.00 AMA PRA Category 1 Credit™
  • 22.00 Attendance
Please login or create an account to take this course.